Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks

Mandeep Singh, Deepak L. Bhatt, Gregg W. Stone, Charanjit S. Rihal, Bernard J. Gersh, Ryan J. Lennon, Jagat Narula, Valentin Fuster

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

It is estimated that in the United States, each year, approximately 620,000 persons will experience an acute coronary syndrome and approximately 70% of these will have non–ST-elevation acute coronary syndrome. Cardiovascular disease still accounts for 1 of every 3 deaths in the United States, and there is an urgent need to improve the prognosis of patients presenting with acute coronary syndrome. Cardiovascular mortality and ischemic complications are common after acute coronary syndrome, and the advent of newer antithrombotic therapies has reduced ischemic complications, but at the expense of greater bleeding. The new antithrombotic agents also raise the challenge of choosing between multiple potential therapeutic combinations to minimize recurrent ischemia without a concomitant increase in bleeding, a decision that often varies according to an individual patient's relative propensity for ischemia versus hemorrhage. In this review, we will synthesize the available information to arm health care providers with the contemporary knowledge on antithrombotic therapy and individualize treatment decisions.

Original languageEnglish (US)
Pages (from-to)1413-1447
Number of pages35
JournalMayo Clinic Proceedings
Volume91
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Acute Coronary Syndrome
Hemorrhage
Ischemia
Fibrinolytic Agents
Therapeutics
Health Personnel
Cardiovascular Diseases
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Singh, M., Bhatt, D. L., Stone, G. W., Rihal, C. S., Gersh, B. J., Lennon, R. J., ... Fuster, V. (2016). Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks. Mayo Clinic Proceedings, 91(10), 1413-1447. https://doi.org/10.1016/j.mayocp.2016.06.013

Antithrombotic Approaches in Acute Coronary Syndromes : Optimizing Benefit vs Bleeding Risks. / Singh, Mandeep; Bhatt, Deepak L.; Stone, Gregg W.; Rihal, Charanjit S.; Gersh, Bernard J.; Lennon, Ryan J.; Narula, Jagat; Fuster, Valentin.

In: Mayo Clinic Proceedings, Vol. 91, No. 10, 01.10.2016, p. 1413-1447.

Research output: Contribution to journalReview article

Singh, M, Bhatt, DL, Stone, GW, Rihal, CS, Gersh, BJ, Lennon, RJ, Narula, J & Fuster, V 2016, 'Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks', Mayo Clinic Proceedings, vol. 91, no. 10, pp. 1413-1447. https://doi.org/10.1016/j.mayocp.2016.06.013
Singh, Mandeep ; Bhatt, Deepak L. ; Stone, Gregg W. ; Rihal, Charanjit S. ; Gersh, Bernard J. ; Lennon, Ryan J. ; Narula, Jagat ; Fuster, Valentin. / Antithrombotic Approaches in Acute Coronary Syndromes : Optimizing Benefit vs Bleeding Risks. In: Mayo Clinic Proceedings. 2016 ; Vol. 91, No. 10. pp. 1413-1447.
@article{9087dc932fc4471689493901083cf49d,
title = "Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks",
abstract = "It is estimated that in the United States, each year, approximately 620,000 persons will experience an acute coronary syndrome and approximately 70{\%} of these will have non–ST-elevation acute coronary syndrome. Cardiovascular disease still accounts for 1 of every 3 deaths in the United States, and there is an urgent need to improve the prognosis of patients presenting with acute coronary syndrome. Cardiovascular mortality and ischemic complications are common after acute coronary syndrome, and the advent of newer antithrombotic therapies has reduced ischemic complications, but at the expense of greater bleeding. The new antithrombotic agents also raise the challenge of choosing between multiple potential therapeutic combinations to minimize recurrent ischemia without a concomitant increase in bleeding, a decision that often varies according to an individual patient's relative propensity for ischemia versus hemorrhage. In this review, we will synthesize the available information to arm health care providers with the contemporary knowledge on antithrombotic therapy and individualize treatment decisions.",
author = "Mandeep Singh and Bhatt, {Deepak L.} and Stone, {Gregg W.} and Rihal, {Charanjit S.} and Gersh, {Bernard J.} and Lennon, {Ryan J.} and Jagat Narula and Valentin Fuster",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.mayocp.2016.06.013",
language = "English (US)",
volume = "91",
pages = "1413--1447",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "10",

}

TY - JOUR

T1 - Antithrombotic Approaches in Acute Coronary Syndromes

T2 - Optimizing Benefit vs Bleeding Risks

AU - Singh, Mandeep

AU - Bhatt, Deepak L.

AU - Stone, Gregg W.

AU - Rihal, Charanjit S.

AU - Gersh, Bernard J.

AU - Lennon, Ryan J.

AU - Narula, Jagat

AU - Fuster, Valentin

PY - 2016/10/1

Y1 - 2016/10/1

N2 - It is estimated that in the United States, each year, approximately 620,000 persons will experience an acute coronary syndrome and approximately 70% of these will have non–ST-elevation acute coronary syndrome. Cardiovascular disease still accounts for 1 of every 3 deaths in the United States, and there is an urgent need to improve the prognosis of patients presenting with acute coronary syndrome. Cardiovascular mortality and ischemic complications are common after acute coronary syndrome, and the advent of newer antithrombotic therapies has reduced ischemic complications, but at the expense of greater bleeding. The new antithrombotic agents also raise the challenge of choosing between multiple potential therapeutic combinations to minimize recurrent ischemia without a concomitant increase in bleeding, a decision that often varies according to an individual patient's relative propensity for ischemia versus hemorrhage. In this review, we will synthesize the available information to arm health care providers with the contemporary knowledge on antithrombotic therapy and individualize treatment decisions.

AB - It is estimated that in the United States, each year, approximately 620,000 persons will experience an acute coronary syndrome and approximately 70% of these will have non–ST-elevation acute coronary syndrome. Cardiovascular disease still accounts for 1 of every 3 deaths in the United States, and there is an urgent need to improve the prognosis of patients presenting with acute coronary syndrome. Cardiovascular mortality and ischemic complications are common after acute coronary syndrome, and the advent of newer antithrombotic therapies has reduced ischemic complications, but at the expense of greater bleeding. The new antithrombotic agents also raise the challenge of choosing between multiple potential therapeutic combinations to minimize recurrent ischemia without a concomitant increase in bleeding, a decision that often varies according to an individual patient's relative propensity for ischemia versus hemorrhage. In this review, we will synthesize the available information to arm health care providers with the contemporary knowledge on antithrombotic therapy and individualize treatment decisions.

UR - http://www.scopus.com/inward/record.url?scp=84994257425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994257425&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2016.06.013

DO - 10.1016/j.mayocp.2016.06.013

M3 - Review article

C2 - 27712639

AN - SCOPUS:84994257425

VL - 91

SP - 1413

EP - 1447

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 10

ER -